Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Small cell lung cancer (SCLC) is an aggressive disease in which, after initial sensitivity to platinum/etoposide chemotherapy, patients frequently relapse with drug-resistant disease. Deregulation of the Bcl-2 pathway is implicated in the pathogenesis of SCLC, and early phase studies of Bcl-2 inhib...

Full description

Bibliographic Details
Main Authors:	Emma J. Dean, Jeff Cummings, Anne Roulston, Mark Berger, Malcolm Ranson, Fiona Blackhall, Caroline Dive
Format:	Article
Language:	English
Published:	Elsevier 2011-04-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558611800151

Similar Items

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
by: Ruth E Board, et al.
Published: (2007-01-01)

Circulating Tumor Cells, Enumeration and Beyond
by: Jian-Mei Hou, et al.
Published: (2010-06-01)

Synthesis of Obatoclax Analogues Targeting Myeloid Cell Leukemia-1
by: Wei-Lin Chen, et al.
Published: (2010)

Circulating tumour cells: their utility in cancer management and predicting outcomes
by: Matthew G. Krebs, et al.
Published: (2010-11-01)

OBATOCLAX REDUCES CELL VIABILITY OF ACUTE MYELOID LEUKEMIA CELLS INDEPENDENTLY OF THEIR SENSITIVITY TO VENETOCLAX
by: K. Lima, et al.
Published: (2020-11-01)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
by: Rocío Jiménez-Guerrero, et al.
Published: (2018-12-01)

Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling
by: Song Chen, et al.
Published: (2020-09-01)

Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
by: Bruno Christian Koehler, et al.
Published: (2014-01-01)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
by: Petter I. Andersen, et al.
Published: (2019-10-01)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization.
by: Vasileios A Stamelos, et al.
Published: (2016-01-01)

Obatoclax derivatives and copper(II) complex mediates DNA cleavage
by: Jung-Hua Chang, et al.
Published: (2012)

Synthesis of obatoclax analogues as SHP-1 enhancers for hepatocellular carcinoma
by: Szu-Hsien Wu, et al.
Published: (2013)

OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
by: David Wroblewski, et al.
Published: (2013-01-01)

Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
by: Finny S. Varghese, et al.
Published: (2021-02-01)

Biological Significance and Mechanistic Study on Obatoclax-induced Downregulation of Survivin in Human Colon Cancer Cell Lines
by: Chiao-Wen Huang, et al.
Published: (2014)

Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular Cancer
by: Esther C. de Haas, et al.
Published: (2008-10-01)

Human Melanoma Cells under Endoplasmic Reticulum Stress Are More Susceptible to Apoptosis Induced by the BH3 Mimetic Obatoclax
by: Chen Chen Jiang, et al.
Published: (2009-09-01)

Biological Significance and Mechanistic Study on Obatoclax-induced Cyclin D1 Downregulation in Human Colon Cancer Cell Lines
by: Ya Chu Chang, et al.
Published: (2016)

Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity.
by: Gretchen Ehrenkaufer, et al.
Published: (2020-03-01)

Mechanisms underlying sensitivity and resistance to the pro-survival BCL_Z antagonist obatoclax
by: McCoy, Francis G. P.
Published: (2011)

Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value
by: Michael J. Walker, et al.
Published: (2015-08-01)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
by: Alex J Eustace, et al.
Published: (2018-10-01)

Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care?
by: Matt Church, et al.
Published: (2020-12-01)

Evaluation of apoptosis imaging biomarkers in a genetic model of cell death
by: Vessela Vassileva, et al.
Published: (2019-02-01)

Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells
by: Chi-Hung R. Or, et al.
Published: (2016-12-01)

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
by: Jingye Li, et al.
Published: (2021-08-01)

Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
by: Xiaohong Xie, et al.
Published: (2021-05-01)

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
by: Jialiang Yang, et al.
Published: (2021-08-01)

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis
by: Lingling Wan, et al.
Published: (2021-05-01)

Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds.
by: Imane Song, et al.
Published: (2017-01-01)

Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
by: Yang Hong, et al.
Published: (2021-03-01)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
by: Helen Adderley, et al.
Published: (2019-03-01)

Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights
by: Francesca Chemi, et al.
Published: (2021-05-01)

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer
by: Ji Zhang, et al.
Published: (2018-06-01)

Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer
by: Shimaa El-Shafey Soliman, et al.
Published: (2018-09-01)

Molecular analysis of single circulating tumour cells following long‐term storage of clinical samples
by: Barbara Mesquita, et al.
Published: (2017-12-01)

Circulating microRNAs as stable circulating biomarkers for lung cancer diagnosis
by: Cheng Chi Yen, et al.
Published: (2010)

Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer
by: Xiaotong Duan, et al.
Published: (2021-07-01)

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
by: Shuai Yuan, et al.
Published: (2020-12-01)

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
by: Muyun Peng, et al.
Published: (2020-09-01)